SecBot SecBot
6-K ·Filed May 13, 2026

TKPHF

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001395064-26-000147
Notable filing: 6-K
Actionable Insight • Neutral

Routine compensation plan continuation with minimal share acquisition (0.8B yen). No material impact on financials or stock. Monitor next earnings for any guidance changes.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
TKPHF ▲ +9.82% at T+60d
NEUTRAL call +9.82% · α vs SPY +5.38% · entry $32.68 → $35.89
Entry = T+0 close
May 13, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.78%
$32.68
settled 6mo ago
T+5d
-1.29%
call -1.29% · α -0.13%
$32.26
settled 5mo ago
T+20d
-5.69%
call -5.69% · α -5.08%
$30.82
settled 5mo ago
T+60d
+9.82%
call +9.82% · α +5.38%
$35.89
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Takeda filed a 6-K announcing the continuation of its stock compensation plan for directors and stock grant system for management in Japan, extending the trust terms by three years to August 2029. The company plans to entrust an additional 0.8 billion yen (~$5.3M) to the BIP Trust for share acquisitions. This is a routine administrative filing with no material financial impact.

Key Facts

  • Board resolved to continue stock compensation plan for directors and stock grant system for management in Japan in 2026
  • Trust terms for BIP Trust and ESOP Trust extended from August 2026 to August 2029
  • Company plans to entrust an additional 0.8 billion yen to the BIP Trust for share acquisitions
  • Maximum total shares vested from BIP Trust limited to 5 billion yen (4.5B for Plan I, 0.3B for Plan II, 0.2B for Plan III)
  • No additional entrustment or share acquisition for the ESOP Trust upon continuation

Financial Impact

0.8 billion yen (~$5.3M) additional trust money for BIP Trust; 5 billion yen upper limit for total BIP Trust contributions

dilution

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000147
Document: form6k-2_051326.htm0001395064-26-000147
Document: 0001395064-26-000147-index-headers.html0001395064-26-000147
Document: 0001395064-26-000147-index.html0001395064-26-000147
Document: 0001395064-26-000147.txt0001395064-26-000147
10 reports for TKPHF
Performance horizon
50% Hit rate @ T+5 2 of 4 directional calls Went positive at some point 2 of 4 best @ T+20▲ +5.95%May 26, 2026
Filters
Rows
Reports for TKPHF — sortable, filterable
TypeNow
Jun 9, 2026
20w ago
6-K
NEUTRAL ★ 3/10
$31.30 $32.48▲ +3.77%▲ +1.97%$41.15 (+31.47%)
Jun 5, 2026
20w ago
6-K
BEARISH ★ 6/10
$30.47 $34.28▼ −12.50%▼ −11.93%$41.15 (−35.05%)
Jun 5, 2026
20w ago
6-K
BEARISH ★ 6/10
$30.47 $34.28▼ −12.50%▼ −11.93%$41.15 (−35.05%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$30.47 $30.47· 0.00%▲ +2.75%$41.15 (+35.05%)
May 26, 2026
22w ago
6-K
MIXED ★ 6/10
$32.10 $30.47▼ −5.08%▼ −6.29%$41.15 (+28.19%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 5/10
$32.10 $30.47▼ −5.08%▼ −6.29%$41.15 (+28.19%)
May 26, 2026
22w ago
6-K
MIXED ★ 6/10
$32.10 $30.47▼ −5.08%▼ −6.29%$41.15 (+28.19%)
May 26, 2026
22w ago
6-K
BEARISH ★ 6/10
$32.10 $30.47▲ +5.08%▲ +6.29%$41.15 (−28.19%)
May 19, 2026
23w ago
6-K
BEARISH ★ 8/10
$32.26 $32.10▲ +0.50%▲ +2.79%$41.15 (−27.56%)
May 13, 2026
23w ago
6-K
NEUTRAL ★ 2/10
$32.68 $32.26▼ −1.29%▼ −0.13%$41.15 (+25.92%)
Showing 10 of 10

US Market Status

Market Closed — Opens Thu (10h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026